The effect of intakes of fish and Camelina sativa oil on atherogenic and anti-atherogenic functions of LDL and HDL particles: A randomized controlled trial

Atherosclerosis. 2019 Feb:281:56-61. doi: 10.1016/j.atherosclerosis.2018.12.017. Epub 2018 Dec 23.

Abstract

Background and aims: Omega-3 fatty acids are known to have several cardioprotective effects. Our aim was to investigate the effects of intakes of fish and Camelina sativa oil (CSO), rich in alpha-linolenic acid, on the atherogenic and anti-atherogenic functions of LDL and HDL particles.

Methods: Altogether, 88 volunteers with impaired glucose metabolism were randomly assigned to CSO (10 g of alpha-linolenic acid/day), fatty fish (4 fish meals/week), lean fish (4 fish meals/week) or control group for 12 weeks. 79 subjects completed the study. The binding of lipoproteins to aortic proteoglycans, LDL aggregation and activation of endothelial cells by LDL and cholesterol efflux capacity of HDL were determined in vitro.

Results: Intake of CSO decreased the binding of lipoproteins to aortic proteoglycans in a non-normalized model (p = 0.006). After normalizing with serum concentrations of non-HDL cholesterol, apolipoprotein B (apoB) or LDL cholesterol, which decreased in the CSO group, the change was no longer statistically significant. In the fish groups, there were no changes in the binding of lipoproteins to proteoglycans. Regarding other lipoprotein functions, there were no changes in any of the groups.

Conclusions: Intake of CSO decreases the binding of lipoproteins to aortic proteoglycans by decreasing serum LDL cholesterol concentration, which suggests that the level of apoB-containing lipoproteins in the circulation is the main driver of lipoprotein retention within the arterial wall. Intake of fish or CSO has no effects on other lipoprotein functions.

Trial registration: ClinicalTrials.gov NCT01768429.

Keywords: Cholesterol efflux; Diet; Human; Interleukin-8; LDL aggregation; Omega-3 fatty acid; Proteoglycan.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aorta / metabolism
  • Biomarkers / blood
  • Brassicaceae*
  • Cells, Cultured
  • Cholesterol / blood*
  • Diet, Healthy*
  • Dietary Supplements* / adverse effects
  • Docosahexaenoic Acids / administration & dosage*
  • Docosahexaenoic Acids / adverse effects
  • Eicosapentaenoic Acid / administration & dosage*
  • Eicosapentaenoic Acid / adverse effects
  • Endothelial Cells / metabolism
  • Female
  • Finland
  • Humans
  • Lipoproteins, HDL / blood*
  • Lipoproteins, LDL / blood*
  • Male
  • Middle Aged
  • Plant Oils / administration & dosage*
  • Plant Oils / adverse effects
  • Protein Binding
  • Proteoglycans / metabolism
  • Recommended Dietary Allowances
  • Seafood*

Substances

  • Biomarkers
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Plant Oils
  • Proteoglycans
  • Docosahexaenoic Acids
  • Cholesterol
  • Eicosapentaenoic Acid

Associated data

  • ClinicalTrials.gov/NCT01768429